Quantifying the effect of metformin treatment and dose on glycemic control.

Quantifying the effect of metformin treatment and dose on glycemic control.

OBJECTIVE: Metformin is the first-line oral medication recommended for glycemic control in patients with type 2 diabetes. We reviewed the literature to quantify the effect of metformin treatment on glycated hemoglobin (HbA(1c)) levels in all types of diabetes and examine the impact of differing dose...

Full description

Bibliographic Details
Main Authors:	Hirst, J, Farmer, A, Ali, R, Roberts, N, Stevens, R
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
by: Kahn, SE, et al.
Published: (2006)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
by: Zhou, K, et al.
Published: (2011)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
by: Zhou, K, et al.
Published: (2011)

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
by: Cook, M, et al.
Published: (2005)

Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis
by: Hirst, J, et al.
Published: (2015)

Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
by: Blacklock, C, et al.
Published: (2011)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
by: Turner, R, et al.
Published: (1999)

HbA(1c) before and after starting treatment with metformin in a large diabetes type 2 cohort
by: Vazquez-Montes, M, et al.
Published: (2012)

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
by: Hanefeld, M, et al.
Published: (2004)

Efficacy of sulfonylurea treatment for glycaemic control in diabetes: a systematic review and meta-analysis
by: Farmer, A, et al.
Published: (2012)

Metformin use in chronic kidney disease: new evidence to guide dosing.
by: Herrington, W, et al.
Published: (2013)

Metformin and mortality. Reply to Lund SS [letter]
by: Stevens, R, et al.
Published: (2013)

Metformin and mortality. Reply to Lund SS [letter].
by: Stevens, R, et al.
Published: (2013)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
by: Turner, R, et al.
Published: (1999)

Pioglitazone and metformin.
by: Hill, N, et al.
Published: (2007)

Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
by: Farmer, A, et al.
Published: (2014)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
by: Holman, R
Published: (2007)

Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials
by: Stevens, R, et al.
Published: (2012)

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
by: Stevens, R, et al.
Published: (2012)

Performance of Glycemic Control Protocol and Virtual Trial
by: Fatanah, M. Suhaimi, et al.
Published: (2017)

The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response
by: Ningrum, Vitarani Dwi Ananda, et al.
Published: (2022)

Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
by: Stevens, R, et al.
Published: (2012)

Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
by: Zhou, K, et al.
Published: (2009)

The role of ATM in response to metformin treatment and activation of AMPK.
by: Zhou, K, et al.
Published: (2012)

Acarbose was effective in maintaining glycemic control in type 2 diabetes mellitus but was associated with adverse effects
by: Holman, R, et al.
Published: (1999)

Cost utility analysis of intensive blood-glucose control, tight blood pressure control and metformin in patients with Type 2 diabetes
by: Clarke, P, et al.
Published: (2004)

Of mice and men: is there a future for metformin in the treatment of hepatic steatosis?
by: Green, C, et al.
Published: (2018)

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
by: Clarke, P, et al.
Published: (2001)

A systematic review and meta-analysis of the effects of diuretics and beta-blockers on glycaemic control in diabetes mellitus
by: Hirst, J, et al.
Published: (2014)

A randomized controlled trial of the effect of real-time telemedicine support on glycemic control in young adults with type 1 diabetes (ISRCTN 46889446).
by: Farmer, A, et al.
Published: (2005)

Effect of metformin on breast cancer metabolism
by: Lord, S, et al.
Published: (2014)

Metformin and risk of cardiovascular disease.
by: Turner, R, et al.
Published: (1999)

Low-dose short-course metformin decrease the risk of atherosclerosis in the non-obese prediabetic individuals
by: Perpustakaan UGM, i-lib
Published: (2008)

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
by: Belcher, G, et al.
Published: (2005)

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM
by: Lord, SR, et al.
Published: (2011)

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM
by: Lord, SR, et al.
Published: (2011)

Depressed mood is a factor in glycemic control in type 1 diabetes.
by: Tilburg, V, et al.
Published: (2001)

Using oxygen dose histograms to quantify voxelised ultra-high dose rate (FLASH) effects in multiple radiation modalities
by: Van den Heuvel, F, et al.
Published: (2022)

The incidence of infection is higher in older people with poor glycemic control
by: Mcgovern, AP, et al.
Published: (2016)

No glycemic benefit from guar administration in NIDDM.
by: Holman, R, et al.
Published: (1987)